A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Annemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlan...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-04-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-combined-analysis-of-four-observational-studies-evaluating-the-intra-peer-reviewed-article-OPTH |
| _version_ | 1818421570944630784 |
|---|---|
| author | Stevens A Iliev ME de Jong L Grobeiu I Hommer A |
| author_facet | Stevens A Iliev ME de Jong L Grobeiu I Hommer A |
| author_sort | Stevens A |
| collection | DOAJ |
| description | Annemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlands; 4Allergan Holdings Ltd, Marlow, UK; 5Private Office, Vienna, Austria Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. Keywords: bimatoprost 0.01%, intraocular pressure, prostaglandin, bimatoprost, glaucoma treatment, switch therapy |
| first_indexed | 2024-12-14T13:12:28Z |
| format | Article |
| id | doaj.art-da3dc5653ea84b31b93ae7785389c2bf |
| institution | Directory Open Access Journal |
| issn | 1177-5483 |
| language | English |
| last_indexed | 2024-12-14T13:12:28Z |
| publishDate | 2016-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-da3dc5653ea84b31b93ae7785389c2bf2022-12-21T23:00:09ZengDove Medical PressClinical Ophthalmology1177-54832016-04-012016Issue 163564126331A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionStevens AIliev MEde Jong LGrobeiu IHommer AAnnemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlands; 4Allergan Holdings Ltd, Marlow, UK; 5Private Office, Vienna, Austria Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. Keywords: bimatoprost 0.01%, intraocular pressure, prostaglandin, bimatoprost, glaucoma treatment, switch therapyhttps://www.dovepress.com/a-combined-analysis-of-four-observational-studies-evaluating-the-intra-peer-reviewed-article-OPTHbimatoprost 0.01%intraocular pressureprostaglandinbimatoprostglaucoma treatmentswitch therapy |
| spellingShingle | Stevens A Iliev ME de Jong L Grobeiu I Hommer A A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension Clinical Ophthalmology bimatoprost 0.01% intraocular pressure prostaglandin bimatoprost glaucoma treatment switch therapy |
| title | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_full | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_fullStr | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_full_unstemmed | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_short | A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_sort | combined analysis of four observational studies evaluating the intraocular pressure lowering ability and tolerability of bimatoprost 0 01 in patients with primary open angle glaucoma or ocular hypertension |
| topic | bimatoprost 0.01% intraocular pressure prostaglandin bimatoprost glaucoma treatment switch therapy |
| url | https://www.dovepress.com/a-combined-analysis-of-four-observational-studies-evaluating-the-intra-peer-reviewed-article-OPTH |
| work_keys_str_mv | AT stevensa acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT ilievme acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT dejongl acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT grobeiui acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT hommera acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT stevensa combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT ilievme combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT dejongl combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT grobeiui combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT hommera combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension |